Report Code: CMI45061

Published Date: April 2024

Pages: 320+

Category: Healthcare

Report Snapshot

CAGR: 10.2%
2,158.6M
2023
2,378.8M
2024
5,701.5M
2033

Source: CMI

Study Period: 2024-2033
Fastest Growing Market: Asia-Pacific
Largest Market: Europe

Major Players

  • Thermo Fisher Scientific Inc.
  • Merck KGaA
  • STEMCELL Technologies Inc.
  • Sino Biological Inc.
  • Celgene Corporation
  • AbbVie Inc.
  • Others

Exclusive, in-depth market intelligence can help you increase your Revenue.

Download Sample Pdf

Reports Description

As per the current market research conducted by the CMI Team, the global Cancer Stem Cells Market is expected to record a CAGR of 10.2% from 2024 to 2033. In 2024, the market size is projected to reach a valuation of USD 2,378.8 Million. By 2033, the valuation is anticipated to reach USD 5,701.5 Million.

The Cancer Stem Cells Market encompasses the global industry focused on understanding and targeting a subpopulation of cells within tumors known as cancer stem cells. These cells possess self-renewal and differentiation capabilities and are implicated in tumor initiation, progression, metastasis, and treatment resistance.

The market involves the development and commercialization of innovative research tools, therapeutics, and diagnostic assays specifically targeting cancer stem cells. Key players include pharmaceutical companies, biotechnology firms, academic institutions, and research organizations, all working towards advancing our understanding of cancer biology and developing effective strategies for cancer treatment and management.

Cancer Stem Cells Market – Significant Growth Factors

The Cancer Stem Cells Market presents significant growth opportunities due to several factors:

  • Growing Incidence of Cancer: The increasing prevalence of cancer worldwide is a major driver for the Cancer Stem Cells Market, as cancer stem cells play a crucial role in tumor initiation, progression, and recurrence.
  • Advancements in Research Technologies: Continuous advancements in research technologies, such as single-cell sequencing and 3D organoid models, are driving the discovery and characterization of cancer stem cells, fostering market growth.
  • Rising Investments in Cancer Research: Increasing investments by governments, private organizations, and pharmaceutical companies in cancer research initiatives are fueling the development of novel therapies targeting cancer stem cells, driving market expansion.
  • Emphasis on Personalized Medicine: The shift towards personalized medicine approaches in oncology, which involves targeting therapies based on individual patient characteristics, is driving demand for innovative treatments targeting cancer stem cells.
  • Development of Targeted Therapies: The identification of specific biomarkers and signaling pathways associated with cancer stem cells presents opportunities for the development of targeted therapies aimed at eliminating these cells while sparing normal cells.
  • Expansion of Research and Clinical Trials: There is an opportunity to expand research and clinical trials focused on cancer stem cell-targeted therapies, including combination therapies and immunotherapies, to improve treatment outcomes and patient survival rates.

Cancer Stem Cells Market – Mergers and Acquisitions

The Cancer Stem Cells Market has seen several mergers and acquisitions in recent years, with companies seeking to expand their market presence and leverage synergies to improve their product offerings and profitability. Some notable examples of mergers and acquisitions in the Cancer Stem Cells Market include:

  • In 2023, Epigenomics AG introduced a multi-center clinical trial for a “Next-Generation” blood-based diagnostic screening test for colorectal cancer (CRC). This non-invasive option aims to boost screening rates and enhance diagnostic outcomes. The strategic launch significantly expanded the company’s customer base and generated substantial business revenue.
  • In 2022, Gamida Cell’s allogeneic cell therapy Omisirge received FDA approval, promising to enhance access to stem cell transplants and improve patient outcomes. This milestone marks a significant advancement in the field of cell therapy and offers hope for patients in need of transplantation.
  • In 2022, Guardant Health introduced the Shield test, a non-invasive blood-based screening method for detecting colorectal cancer. This test eliminates the need for sedation and dietary changes, offering a less painful and more convenient option. It detects early colorectal cancer signals in the bloodstream, enhancing early detection efforts.

These mergers and acquisitions have helped companies expand their product offerings, improve their market presence, and capitalize on growth opportunities in the Cancer Stem Cells Market. The trend is expected to continue as companies seek to gain a competitive edge in the market.

COMPARATIVE ANALYSIS OF THE RELATED MARKET

Cancer Stem Cells Market Cancer Immunotherapy Market PARP Inhibitors Market
CAGR 10.2% (Approx) CAGR 7.2% (Approx) CAGR 12.1% (Approx)
USD 5,701.5 Million by 2033 USD 314.4 Billion by 2033 USD 23.5 Billion by 2033

Cancer Stem Cells Market – Significant Threats

The Cancer Stem Cells Market faces several significant threats that could impact its growth and profitability in the future. Some of these threats include:

  • Treatment Resistance: Cancer stem cells are known to exhibit resistance to conventional cancer treatments, including chemotherapy and radiation therapy, posing a significant threat to treatment efficacy and patient outcomes.
  • Heterogeneity of Cancer Stem Cells: The heterogeneity of cancer stem cells within tumors presents challenges for targeted therapies, as different subpopulations may respond differently to treatment, leading to treatment failure and disease recurrence.
  • Limited Understanding of Cancer Stem Cell Biology: Despite advancements, there is still much to learn about the biology and behavior of cancer stem cells, hindering the development of effective therapeutic strategies and diagnostic tools.
  • Regulatory Challenges: Regulatory hurdles and lengthy approval processes for new cancer stem cell-targeted therapies may delay their market entry, limiting patient access to potentially beneficial treatments.
  • Ethical Concerns: Ethical considerations surrounding the use of stem cells, particularly embryonic stem cells, in cancer research and therapy development may restrict funding and public support for such initiatives, impeding progress in the field.

Global Cancer Stem Cells Market 2024–2033 (By Biomarker Type)

www.custommarketinsight.com

Category-Wise Insights

By Type of Cancer

  • Breast Cancer: Breast cancer stem cells are a subset of cells within breast tumors that possess self-renewal and tumor-initiating capabilities. Emerging trends in the Cancer Stem Cells Market for breast cancer include extensive research efforts to identify specific surface markers such as CD44/CD24 and ALDH1, which are associated with cancer stem cell populations.
  • Lung Cancer: Lung cancer stem cells are believed to drive tumor initiation, progression, and resistance to therapy. In the Cancer Stem Cells Market, there is increasing attention on understanding the molecular mechanisms underlying lung cancer stem cell biology, with a particular focus on markers such as CD133. Moreover, researchers are exploring innovative combination therapies and drug delivery systems to effectively target and eliminate lung cancer stem cells, thereby enhancing treatment response and prolonging survival rates for patients with lung cancer.
  • Brain Cancer: Brain cancer stem cells are a small subpopulation of cells within brain tumors that exhibit self-renewal and tumorigenic properties. Notably, in the Cancer Stem Cells Market, there is a growing emphasis on elucidating the role of specific markers such as CD133 in brain cancer stem cell identification and targeting.
  • Prostate Cancer: Prostate cancer stem cells are implicated in tumor initiation, progression, and therapeutic resistance. Within the Cancer Stem Cells Market, ongoing research efforts are focused on identifying unique surface markers such as CD44/CD133 associated with prostate cancer stem cell populations. Moreover, there is a significant emphasis on developing personalized treatment approaches, including precision medicine strategies tailored to target prostate cancer stem cells specifically.
  • Colorectal Cancer: Colorectal cancer stem cells play a critical role in tumor growth, metastasis, and therapy resistance. Within the Cancer Stem Cells Market, researchers are actively investigating specific markers such as LGR5 associated with colorectal cancer stem cell populations. Additionally, there is a concerted effort to develop innovative immunotherapeutic approaches that harness the immune system to target and eliminate colorectal cancer stem cells effectively.
  • Others: Various other cancer types, including ovarian, pancreatic, and melanoma, also harbor cancer stem cell populations that contribute to tumor initiation, progression, and therapeutic resistance. In the Cancer Stem Cells Market, research efforts are focused on identifying unique molecular signatures and pathways specific to each cancer type. Additionally, there is a drive to develop tailored therapeutic interventions, including targeted therapies and immunotherapies, designed to selectively target and eradicate cancer stem cells within these tumor types.

By Treatment Type

  • Chemotherapy: Chemotherapy involves using drugs to kill cancer cells. In the Cancer Stem Cells Market, trends include the development of targeted chemotherapy agents to specifically target cancer stem cells while minimizing toxicity to normal cells, and the exploration of combination therapies to enhance treatment efficacy.
  • Immunotherapy: Immunotherapy boosts the body’s immune system to fight cancer. In the Cancer Stem Cells Market, trends include the development of immunotherapies targeting cancer stem cell-specific antigens, the use of immune checkpoint inhibitors to disrupt cancer stem cell-mediated immunosuppression and the exploration of adoptive cell therapies.
  • Targeted Therapy: Targeted therapy blocks specific molecules involved in cancer cell growth. In the Cancer Stem Cells Market, trends include the discovery of novel targets and biomarkers expressed by cancer stem cells, the development of small molecule inhibitors and monoclonal antibodies targeting these molecules, and the exploration of combination therapies.
  • Stem Cell Transplantation: Stem cell transplantation involves replacing diseased bone marrow with healthy stem cells. In the Cancer Stem Cells Market, trends include the investigation of stem cell-based therapies to target and eliminate cancer stem cells, the optimization of transplantation protocols for enhanced anti-tumor efficacy, and the exploration of gene-modified stem cells for targeted delivery of therapeutic agents.
  • Others: Other treatment types in the Cancer Stem Cells Market may include radiotherapy, surgery, and hormone therapy. Trends in these areas include the development of novel radiotherapy techniques to target cancer stem cells, the refinement of surgical approaches for tumor debulking and removal, and the investigation of hormone-based therapies to disrupt cancer stem cell signaling pathways.

Global Cancer Stem Cells Market 2024–2033 (By Type of Cancer)

www.custommarketinsight.com

By Biomarker Type

  • CD44: CD44 is a cell surface glycoprotein involved in cell adhesion and migration. In the Cancer Stem Cells Market, CD44 is a biomarker associated with cancer stem cells. Trends include research focusing on targeting CD44-positive cancer stem cells and developing therapeutic strategies to inhibit CD44-mediated tumor progression.
  • CD133: CD133, also known as Prominin-1, is a transmembrane glycoprotein expressed on the surface of stem cells, including cancer stem cells. In the Cancer Stem Cells Market, CD133 is used as a biomarker to identify and isolate cancer stem cell populations. Trends include studies exploring the role of CD133-positive cancer stem cells in tumor initiation, progression, and treatment resistance, as well as efforts to develop targeted therapies against CD133.
  • ALDH1: ALDH1 (Aldehyde Dehydrogenase 1) is an enzyme involved in detoxifying aldehydes and oxidizing retinol to retinoic acid. In the Cancer Stem Cells Market, ALDH1 is considered a biomarker for cancer stem cells due to its association with tumor-initiating cells and treatment resistance. Trends include research on ALDH1-positive cancer stem cells and the development of ALDH1-targeted therapies for cancer treatment.
  • Others: In addition to CD44, CD133, and ALDH1, various other biomarkers are being explored in the Cancer Stem Cells Market to identify and characterize cancer stem cell populations. These biomarkers include markers of stemness, self-renewal, and tumor-initiating capacity, as well as markers specific to different cancer types. Trends include the discovery and validation of novel biomarkers and their incorporation into cancer stem cell research and therapeutic development.

By End User

  • Hospitals: Hospitals provide clinical care and treatment for cancer patients, often utilizing research findings from cancer stem cell studies to inform treatment decisions. Trends include integrating personalized medicine approaches and adopting novel therapies targeting cancer stem cells to improve patient outcomes.
  • Cancer Research Institutes: These institutes focus on advancing scientific knowledge and developing innovative therapies for cancer, including those targeting cancer stem cells. Trends include exploring novel biomarkers, developing targeted therapies, and conducting clinical trials to evaluate the efficacy of cancer stem cell-targeted treatments.
  • Biotechnology Companies: Biotechnology firms play a critical role in developing and commercializing novel therapies and research tools targeting cancer stem cells. Trends include investing in drug discovery programs, advancing cell-based therapies, and leveraging innovative technologies for cancer stem cell research and therapy development.
  • Academic Research Institutes: Academic institutions conduct fundamental and translational research to deepen our understanding of cancer stem cells and develop novel therapeutic approaches. Trends include interdisciplinary collaborations, the use of advanced imaging techniques, and the development of preclinical models to study cancer stem cell biology and drug response.

Report Scope

Feature of the Report Details
Market Size in 2024 USD 2,378.8 Million
Projected Market Size in 2033 USD 5,701.5 Million
Market Size in 2023 USD 2,158.6 Million
CAGR Growth Rate 10.2% CAGR
Base Year 2023
Forecast Period 2024-2033
Key Segment By Type of Cancer, Treatment Type, Biomarker Type, End User and Region
Report Coverage Revenue Estimation and Forecast, Company Profile, Competitive Landscape, Growth Factors and Recent Trends
Regional Scope North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America
Buying Options Request tailored purchasing options to fulfil your requirements for research.

Cancer Stem Cells Market – Regional Analysis

The Cancer Stem Cells Market is segmented into various regions, including North America, Europe, Asia-Pacific, and LAMEA. Here is a brief overview of each region:

  • North America: In North America, trends in the Cancer Stem Cells Market include a strong emphasis on personalized medicine approaches, with a focus on developing targeted therapies and precision oncology strategies tailored to individual patient profiles. Additionally, there is a significant investment in cutting-edge research technologies and collaborative efforts between academic institutions and biotechnology companies to advance cancer stem cell research and therapy development.
  • Europe: In Europe, key trends in the Cancer Stem Cells Market include the expansion of translational research initiatives bridging basic science discoveries with clinical applications, with a particular focus on developing novel stem cell-based therapies and precision medicine approaches for cancer treatment. Furthermore, there is growing investment in multi-center clinical trials and collaborative research consortia to accelerate the translation of cancer stem cell research into clinical practice.
  • Asia-Pacific: In the Asia-Pacific region, trends in the Cancer Stem Cells Market include the rapid growth of biotechnology and pharmaceutical industries, driving investment in innovative cancer stem cell research and drug discovery programs. Additionally, there is increasing adoption of regenerative medicine approaches, including stem cell-based therapies, for cancer treatment. Moreover, there is a rising emphasis on international collaborations and partnerships to leverage expertise and resources for advancing cancer stem cell research and therapy development.
  • LAMEA (Latin America, Middle East, and Africa): In the LAMEA region, trends in the Cancer Stem Cells Market include a growing focus on cancer research and healthcare infrastructure development, particularly in emerging economies. There is increasing investment in the biotechnology and pharmaceutical sectors, driving advancements in cancer stem cell research and therapy development. Additionally, there is a rising emphasis on capacity building and training programs to foster local expertise in cancer stem cell research and clinical practice.

Global Cancer Stem Cells Market 2024–2033 (By Million)

www.custommarketinsight.com

Competitive Landscape – Cancer Stem Cells Market

The Cancer Stem Cells Market is highly competitive, with a large number of manufacturers and retailers operating globally. Some of the key players in the market include:

  • Thermo Fisher Scientific Inc.
  • Merck KGaA
  • STEMCELL Technologies Inc.
  • Sino Biological Inc.
  • Celgene Corporation
  • AbbVie Inc.
  • Incyte Corporation
  • Novartis AG
  • Pfizer Inc.
  • Bionique Testing Laboratories Inc.
  • Miltenyi Biotec GmbH
  • Lonza Group AG
  • OncoMed Pharmaceuticals Inc.
  • Daiichi Sankyo Company Limited
  • Verastem Inc.
  • Others

These companies operate in the market through various strategies such as product innovation, mergers and acquisitions, and partnerships.

New players entering the Cancer Stem Cells Market are leveraging innovation to establish their presence. These players often focus on developing novel research tools, therapeutic candidates, and diagnostic assays targeting cancer stem cells.

Key players dominating the market include Thermo Fisher Scientific Inc., STEMCELL Technologies Inc., and Merck KGaA, renowned for their extensive product portfolios, strong distribution networks, and strategic collaborations.

These companies maintain their dominance through continuous investment in R&D, strategic acquisitions, and partnerships, enabling them to offer comprehensive solutions and maintain a competitive edge in the market.

The Cancer Stem Cells Market is segmented as follows:

By Type of Cancer

  • Breast Cancer
  • Lung Cancer
  • Brain Cancer
  • Prostate Cancer
  • Colorectal Cancer
  • Others

By Treatment Type

  • Chemotherapy
  • Immunotherapy
  • Targeted Therapy
  • Stem Cell Transplantation
  • Others

By Biomarker Type

  • CD44
  • CD133
  • ALDH1
  • Others

By End User

  • Hospitals
  • Cancer Research Institutes
  • Biotechnology Companies
  • Academic Research Institutes

Regional Coverage:

North America

  • U.S.
  • Canada
  • Mexico
  • Rest of North America

Europe

  • Germany
  • France
  • U.K.
  • Russia
  • Italy
  • Spain
  • Netherlands
  • Rest of Europe

Asia Pacific

  • China
  • Japan
  • India
  • New Zealand
  • Australia
  • South Korea
  • Taiwan
  • Rest of Asia Pacific

The Middle East & Africa

  • Saudi Arabia
  • UAE
  • Egypt
  • Kuwait
  • South Africa
  • Rest of the Middle East & Africa

Latin America

  • Brazil
  • Argentina
  • Rest of Latin America

Table of Contents

  • Chapter 1. Preface
    • 1.1 Report Description and Scope
    • 1.2 Research scope
    • 1.3 Research methodology
      • 1.3.1 Market Research Type
      • 1.3.2 Market Research Methodology
  • Chapter 2. Executive Summary
    • 2.1 Global Cancer Stem Cells Market, (2024 – 2033) (USD Million)
    • 2.2 Global Cancer Stem Cells Market: snapshot
  • Chapter 3. Global Cancer Stem Cells Market – Industry Analysis
    • 3.1 Cancer Stem Cells Market: Market Dynamics
    • 3.2 Market Drivers
      • 3.2.1 Growing Incidence of Cancer
      • 3.2.2 Advancements in Research Technologies
      • 3.2.3 Rising Investments in Cancer Research
      • 3.2.4 Emphasis on Personalized Medicine
      • 3.2.5 Development of Targeted Therapies
      • 3.2.6 Expansion of Research and Clinical Trials.
    • 3.3 Market Restraints
    • 3.4 Market Opportunities
    • 3.5 Market Challenges
    • 3.6 Porter’s Five Forces Analysis
    • 3.7 Market Attractiveness Analysis
      • 3.7.1 Market Attractiveness Analysis By Type of Cancer
      • 3.7.2 Market Attractiveness Analysis By Treatment Type
      • 3.7.3 Market Attractiveness Analysis By Biomarker Type
      • 3.7.4 Market Attractiveness Analysis By End User
  • Chapter 4. Global Cancer Stem Cells Market- Competitive Landscape
    • 4.1 Company market share analysis
      • 4.1.1 Global Cancer Stem Cells Market: company market share, 2023
    • 4.2 Strategic development
      • 4.2.1 Acquisitions & mergers
      • 4.2.2 New Product launches
      • 4.2.3 Agreements, partnerships, cullaborations, and joint ventures
      • 4.2.4 Research and development and Regional expansion
    • 4.3 Price trend analysis
  • Chapter 5. Global Cancer Stem Cells Market – Type of Cancer Analysis
    • 5.1 Global Cancer Stem Cells Market Overview: By Type of Cancer
      • 5.1.1 Global Cancer Stem Cells Market Share, By Type of Cancer, 2023 and 2033
    • 5.2 Breast Cancer
      • 5.2.1 Global Cancer Stem Cells Market by Breast Cancer, 2024 – 2033 (USD Million)
    • 5.3 Lung Cancer
      • 5.3.1 Global Cancer Stem Cells Market by Lung Cancer, 2024 – 2033 (USD Million)
    • 5.4 Brain Cancer
      • 5.4.1 Global Cancer Stem Cells Market by Brain Cancer, 2024 – 2033 (USD Million)
    • 5.5 Prostate Cancer
      • 5.5.1 Global Cancer Stem Cells Market by Prostate Cancer, 2024 – 2033 (USD Million)
    • 5.6 Colorectal Cancer
      • 5.6.1 Global Cancer Stem Cells Market by Colorectal Cancer, 2024 – 2033 (USD Million)
    • 5.7 Others
      • 5.7.1 Global Cancer Stem Cells Market by Others, 2024 – 2033 (USD Million)
  • Chapter 6. Global Cancer Stem Cells Market – Treatment Type Analysis
    • 6.1 Global Cancer Stem Cells Market Overview: By Treatment Type
      • 6.1.1 Global Cancer Stem Cells Market Share, By Treatment Type, 2023 and 2033
    • 6.2 Chemotherapy
      • 6.2.1 Global Cancer Stem Cells Market by Chemotherapy, 2024 – 2033 (USD Million)
    • 6.3 Immunotherapy
      • 6.3.1 Global Cancer Stem Cells Market by Immunotherapy, 2024 – 2033 (USD Million)
    • 6.4 Targeted Therapy
      • 6.4.1 Global Cancer Stem Cells Market by Targeted Therapy, 2024 – 2033 (USD Million)
    • 6.5 Stem Cell Transplantation
      • 6.5.1 Global Cancer Stem Cells Market by Stem Cell Transplantation, 2024 – 2033 (USD Million)
    • 6.6 Others
      • 6.6.1 Global Cancer Stem Cells Market by Others, 2024 – 2033 (USD Million)
  • Chapter 7. Global Cancer Stem Cells Market – Biomarker Type Analysis
    • 7.1 Global Cancer Stem Cells Market Overview: By Biomarker Type
      • 7.1.1 Global Cancer Stem Cells Market Share, By Biomarker Type, 2023 and 2033
    • 7.2 CD44
      • 7.2.1 Global Cancer Stem Cells Market by CD44, 2024 – 2033 (USD Million)
    • 7.3 CD133
      • 7.3.1 Global Cancer Stem Cells Market by CD133, 2024 – 2033 (USD Million)
    • 7.4 ALDH1
      • 7.4.1 Global Cancer Stem Cells Market by ALDH1, 2024 – 2033 (USD Million)
    • 7.5 Others
      • 7.5.1 Global Cancer Stem Cells Market by Others, 2024 – 2033 (USD Million)
  • Chapter 8. Global Cancer Stem Cells Market – End User Analysis
    • 8.1 Global Cancer Stem Cells Market Overview: By End User
      • 8.1.1 Global Cancer Stem Cells Market Share, By End User, 2023 and 2033
    • 8.2 Hospitals
      • 8.2.1 Global Cancer Stem Cells Market by Hospitals, 2024 – 2033 (USD Million)
    • 8.3 Cancer Research Institutes
      • 8.3.1 Global Cancer Stem Cells Market by Cancer Research Institutes, 2024 – 2033 (USD Million)
    • 8.4 Biotechnology Companies
      • 8.4.1 Global Cancer Stem Cells Market by Biotechnology Companies, 2024 – 2033 (USD Million)
    • 8.5 Academic Research Institutes
      • 8.5.1 Global Cancer Stem Cells Market by Academic Research Institutes, 2024 – 2033 (USD Million)
  • Chapter 9. Cancer Stem Cell’s Market – Regional Analysis
    • 9.1 Global Cancer Stem Cell’s Market Regional Overview
    • 9.2 Global Cancer Stem Cell’s Market Share, by Region, 2023 & 2033 (USD Million)
    • 9.3. North America
      • 9.3.1 North America Cancer Stem Cell’s Market, 2024 – 2033 (USD Million)
        • 9.3.1.1 North America Cancer Stem Cell’s Market, by Country, 2024 – 2033 (USD Million)
    • 9.4 North America Cancer Stem Cell’s Market, by Type of Cancer, 2024 – 2033
      • 9.4.1 North America Cancer Stem Cell’s Market, by Type of Cancer, 2024 – 2033 (USD Million)
    • 9.5 North America Cancer Stem Cell’s Market, by Treatment Type, 2024 – 2033
      • 9.5.1 North America Cancer Stem Cell’s Market, by Treatment Type, 2024 – 2033 (USD Million)
    • 9.6 North America Cancer Stem Cell’s Market, by Biomarker Type, 2024 – 2033
      • 9.6.1 North America Cancer Stem Cell’s Market, by Biomarker Type, 2024 – 2033 (USD Million)
    • 9.7 North America Cancer Stem Cell’s Market, by End User, 2024 – 2033
      • 9.7.1 North America Cancer Stem Cell’s Market, by End User, 2024 – 2033 (USD Million)
    • 9.8. Europe
      • 9.8.1 Europe Cancer Stem Cell’s Market, 2024 – 2033 (USD Million)
        • 9.8.1.1 Europe Cancer Stem Cell’s Market, by Country, 2024 – 2033 (USD Million)
    • 9.9 Europe Cancer Stem Cell’s Market, by Type of Cancer, 2024 – 2033
      • 9.9.1 Europe Cancer Stem Cell’s Market, by Type of Cancer, 2024 – 2033 (USD Million)
    • 9.10 Europe Cancer Stem Cell’s Market, by Treatment Type, 2024 – 2033
      • 9.10.1 Europe Cancer Stem Cell’s Market, by Treatment Type, 2024 – 2033 (USD Million)
    • 9.11 Europe Cancer Stem Cell’s Market, by Biomarker Type, 2024 – 2033
      • 9.11.1 Europe Cancer Stem Cell’s Market, by Biomarker Type, 2024 – 2033 (USD Million)
    • 9.12 Europe Cancer Stem Cell’s Market, by End User, 2024 – 2033
      • 9.12.1 Europe Cancer Stem Cell’s Market, by End User, 2024 – 2033 (USD Million)
    • 9.13. Asia Pacific
      • 9.13.1 Asia Pacific Cancer Stem Cell’s Market, 2024 – 2033 (USD Million)
        • 9.13.1.1 Asia Pacific Cancer Stem Cell’s Market, by Country, 2024 – 2033 (USD Million)
    • 9.14 Asia Pacific Cancer Stem Cell’s Market, by Type of Cancer, 2024 – 2033
      • 9.14.1 Asia Pacific Cancer Stem Cell’s Market, by Type of Cancer, 2024 – 2033 (USD Million)
    • 9.15 Asia Pacific Cancer Stem Cell’s Market, by Treatment Type, 2024 – 2033
      • 9.15.1 Asia Pacific Cancer Stem Cell’s Market, by Treatment Type, 2024 – 2033 (USD Million)
    • 9.16 Asia Pacific Cancer Stem Cell’s Market, by Biomarker Type, 2024 – 2033
      • 9.16.1 Asia Pacific Cancer Stem Cell’s Market, by Biomarker Type, 2024 – 2033 (USD Million)
    • 9.17 Asia Pacific Cancer Stem Cell’s Market, by End User, 2024 – 2033
      • 9.17.1 Asia Pacific Cancer Stem Cell’s Market, by End User, 2024 – 2033 (USD Million)
    • 9.18. Latin America
      • 9.18.1 Latin America Cancer Stem Cell’s Market, 2024 – 2033 (USD Million)
        • 9.18.1.1 Latin America Cancer Stem Cell’s Market, by Country, 2024 – 2033 (USD Million)
    • 9.19 Latin America Cancer Stem Cell’s Market, by Type of Cancer, 2024 – 2033
      • 9.19.1 Latin America Cancer Stem Cell’s Market, by Type of Cancer, 2024 – 2033 (USD Million)
    • 9.20 Latin America Cancer Stem Cell’s Market, by Treatment Type, 2024 – 2033
      • 9.20.1 Latin America Cancer Stem Cell’s Market, by Treatment Type, 2024 – 2033 (USD Million)
    • 9.21 Latin America Cancer Stem Cell’s Market, by Biomarker Type, 2024 – 2033
      • 9.21.1 Latin America Cancer Stem Cell’s Market, by Biomarker Type, 2024 – 2033 (USD Million)
    • 9.22 Latin America Cancer Stem Cell’s Market, by End User, 2024 – 2033
      • 9.22.1 Latin America Cancer Stem Cell’s Market, by End User, 2024 – 2033 (USD Million)
    • 9.23. The Middle-East and Africa
      • 9.23.1 The Middle-East and Africa Cancer Stem Cell’s Market, 2024 – 2033 (USD Million)
        • 9.23.1.1 The Middle-East and Africa Cancer Stem Cell’s Market, by Country, 2024 – 2033 (USD Million)
    • 9.24 The Middle-East and Africa Cancer Stem Cell’s Market, by Type of Cancer, 2024 – 2033
      • 9.24.1 The Middle-East and Africa Cancer Stem Cell’s Market, by Type of Cancer, 2024 – 2033 (USD Million)
    • 9.25 The Middle-East and Africa Cancer Stem Cell’s Market, by Treatment Type, 2024 – 2033
      • 9.25.1 The Middle-East and Africa Cancer Stem Cell’s Market, by Treatment Type, 2024 – 2033 (USD Million)
    • 9.26 The Middle-East and Africa Cancer Stem Cell’s Market, by Biomarker Type, 2024 – 2033
      • 9.26.1 The Middle-East and Africa Cancer Stem Cell’s Market, by Biomarker Type, 2024 – 2033 (USD Million)
    • 9.27 The Middle-East and Africa Cancer Stem Cell’s Market, by End User, 2024 – 2033
      • 9.27.1 The Middle-East and Africa Cancer Stem Cell’s Market, by End User, 2024 – 2033 (USD Million)
  • Chapter 10. Company Profiles
    • 10.1 Thermo Fisher Scientific Inc.
      • 10.1.1 Overview
      • 10.1.2 Financials
      • 10.1.3 Product Portfolio
      • 10.1.4 Business Strategy
      • 10.1.5 Recent Developments
    • 10.2 Merck KGaA
      • 10.2.1 Overview
      • 10.2.2 Financials
      • 10.2.3 Product Portfolio
      • 10.2.4 Business Strategy
      • 10.2.5 Recent Developments
    • 10.3 STEMCELL Technologies Inc.
      • 10.3.1 Overview
      • 10.3.2 Financials
      • 10.3.3 Product Portfolio
      • 10.3.4 Business Strategy
      • 10.3.5 Recent Developments
    • 10.4 Sino Biological Inc.
      • 10.4.1 Overview
      • 10.4.2 Financials
      • 10.4.3 Product Portfolio
      • 10.4.4 Business Strategy
      • 10.4.5 Recent Developments
    • 10.5 Celgene Corporation
      • 10.5.1 Overview
      • 10.5.2 Financials
      • 10.5.3 Product Portfolio
      • 10.5.4 Business Strategy
      • 10.5.5 Recent Developments
    • 10.6 AbbVie Inc.
      • 10.6.1 Overview
      • 10.6.2 Financials
      • 10.6.3 Product Portfolio
      • 10.6.4 Business Strategy
      • 10.6.5 Recent Developments
    • 10.7 Incyte Corporation
      • 10.7.1 Overview
      • 10.7.2 Financials
      • 10.7.3 Product Portfolio
      • 10.7.4 Business Strategy
      • 10.7.5 Recent Developments
    • 10.8 Novartis AG
      • 10.8.1 Overview
      • 10.8.2 Financials
      • 10.8.3 Product Portfolio
      • 10.8.4 Business Strategy
      • 10.8.5 Recent Developments
    • 10.9 Pfizer Inc.
      • 10.9.1 Overview
      • 10.9.2 Financials
      • 10.9.3 Product Portfolio
      • 10.9.4 Business Strategy
      • 10.9.5 Recent Developments
    • 10.10 Bionique Testing Laboratories Inc.
      • 10.10.1 Overview
      • 10.10.2 Financials
      • 10.10.3 Product Portfolio
      • 10.10.4 Business Strategy
      • 10.10.5 Recent Developments
    • 10.11 Miltenyi Biotec GmbH
      • 10.11.1 Overview
      • 10.11.2 Financials
      • 10.11.3 Product Portfolio
      • 10.11.4 Business Strategy
      • 10.11.5 Recent Developments
    • 10.12 Lonza Group AG
      • 10.12.1 Overview
      • 10.12.2 Financials
      • 10.12.3 Product Portfolio
      • 10.12.4 Business Strategy
      • 10.12.5 Recent Developments
    • 10.13 OncoMed Pharmaceuticals Inc.
      • 10.13.1 Overview
      • 10.13.2 Financials
      • 10.13.3 Product Portfolio
      • 10.13.4 Business Strategy
      • 10.13.5 Recent Developments
    • 10.14 Daiichi Sankyo Company Limited
      • 10.14.1 Overview
      • 10.14.2 Financials
      • 10.14.3 Product Portfolio
      • 10.14.4 Business Strategy
      • 10.14.5 Recent Developments
    • 10.15 Verastem Inc.
      • 10.15.1 Overview
      • 10.15.2 Financials
      • 10.15.3 Product Portfolio
      • 10.15.4 Business Strategy
      • 10.15.5 Recent Developments
    • 10.16 Others.
      • 10.16.1 Overview
      • 10.16.2 Financials
      • 10.16.3 Product Portfolio
      • 10.16.4 Business Strategy
      • 10.16.5 Recent Developments
List Of Figures

Figures No 1 to 37

List Of Tables

Tables No 1 to 102

Report Methodology

In order to get the most precise estimates and forecasts possible, Custom Market Insights applies a detailed and adaptive research methodology centered on reducing deviations. For segregating and assessing quantitative aspects of the market, the company uses a combination of top-down and bottom-up approaches. Furthermore, data triangulation, which examines the market from three different aspects, is a recurring theme in all of our research reports. The following are critical components of the methodology used in all of our studies:

Preliminary Data Mining

On a broad scale, raw market information is retrieved and compiled. Data is constantly screened to make sure that only substantiated and verified sources are taken into account. Furthermore, data is mined from a plethora of reports in our archive and also a number of reputed & reliable paid databases. To gain a detailed understanding of the business, it is necessary to know the entire product life cycle and to facilitate this, we gather data from different suppliers, distributors, and buyers.

Surveys, technological conferences, and trade magazines are used to identify technical issues and trends. Technical data is also gathered from the standpoint of intellectual property, with a focus on freedom of movement and white space. The dynamics of the industry in terms of drivers, restraints, and valuation trends are also gathered. As a result, the content created contains a diverse range of original data, which is then cross-validated and verified with published sources.

Statistical Model

Simulation models are used to generate our business estimates and forecasts. For each study, a one-of-a-kind model is created. Data gathered for market dynamics, the digital landscape, development services, and valuation patterns are fed into the prototype and analyzed concurrently. These factors are compared, and their effect over the projected timeline is quantified using correlation, regression, and statistical modeling. Market forecasting is accomplished through the use of a combination of economic techniques, technical analysis, industry experience, and domain knowledge.

Short-term forecasting is typically done with econometric models, while long-term forecasting is done with technological market models. These are based on a synthesis of the technological environment, legal frameworks, economic outlook, and business regulations. Bottom-up market evaluation is favored, with crucial regional markets reviewed as distinct entities and data integration to acquire worldwide estimates. This is essential for gaining a thorough knowledge of the industry and ensuring that errors are kept to a minimum.

Some of the variables taken into account for forecasting are as follows:

• Industry drivers and constraints, as well as their current and projected impact

• The raw material case, as well as supply-versus-price trends

• Current volume and projected volume growth through 2032

We allocate weights to these variables and use weighted average analysis to determine the estimated market growth rate.

Primary Validation

This is the final step in our report’s estimating and forecasting process. Extensive primary interviews are carried out, both in-person and over the phone, to validate our findings and the assumptions that led to them.
Leading companies from across the supply chain, including suppliers, technology companies, subject matter experts, and buyers, use techniques like interviewing to ensure a comprehensive and non-biased overview of the business. These interviews are conducted all over the world, with the help of local staff and translators, to overcome language barriers.

Primary interviews not only aid with data validation, but also offer additional important insight into the industry, existing business scenario, and future projections, thereby improving the quality of our reports.

All of our estimates and forecasts are validated through extensive research work with key industry participants (KIPs), which typically include:

• Market leaders

• Suppliers of raw materials

• Suppliers of raw materials

• Buyers.

The following are the primary research objectives:

• To ensure the accuracy and acceptability of our data.

• Gaining an understanding of the current market and future projections.

Data Collection Matrix

Perspective Primary research Secondary research
Supply-side
  • Manufacturers
  • Technology distributors and wholesalers
  • Company reports and publications
  • Government publications
  • Independent investigations
  • Economic and demographic data
Demand-side
  • End-user surveys
  • Consumer surveys
  • Mystery shopping
  • Case studies
  • Reference customers


Market Analysis Matrix

Qualitative analysis Quantitative analysis
  • Industry landscape and trends
  • Market dynamics and key issues
  • Technology landscape
  • Market opportunities
  • Porter’s analysis and PESTEL analysis
  • Competitive landscape and component benchmarking
  • Policy and regulatory scenario
  • Market revenue estimates and forecast up to 2032
  • Market revenue estimates and forecasts up to 2032, by technology
  • Market revenue estimates and forecasts up to 2032, by application
  • Market revenue estimates and forecasts up to 2032, by type
  • Market revenue estimates and forecasts up to 2032, by component
  • Regional market revenue forecasts, by technology
  • Regional market revenue forecasts, by application
  • Regional market revenue forecasts, by type
  • Regional market revenue forecasts, by component

Prominent Player

  • Thermo Fisher Scientific Inc.
  • Merck KGaA
  • STEMCELL Technologies Inc.
  • Sino Biological Inc.
  • Celgene Corporation
  • AbbVie Inc.
  • Incyte Corporation
  • Novartis AG
  • Pfizer Inc.
  • Bionique Testing Laboratories Inc.
  • Miltenyi Biotec GmbH
  • Lonza Group AG
  • OncoMed Pharmaceuticals Inc.
  • Daiichi Sankyo Company Limited
  • Verastem Inc.
  • Others

FAQs

The key factors driving the Market are Growing Incidence of Cancer, Advancements in Research Technologies, Rising Investments in Cancer Research, Emphasis on Personalized Medicine, Development of Targeted Therapies, Expansion of Research and Clinical Trials.

The “Chemotherapy” category dominated the market in 2023.

The key players in the market are Thermo Fisher Scientific Inc., Merck KGaA, STEMCELL Technologies Inc., Sino Biological Inc., Celgene Corporation , AbbVie Inc., Incyte Corporation, Novartis AG, Pfizer Inc., Bionique Testing Laboratories Inc., Miltenyi Biotec GmbH, Lonza Group AG, OncoMed Pharmaceuticals Inc., Daiichi Sankyo Company Limited, Verastem Inc., Others.

“North America” had the largest share in the Cancer Stem Cells Market.

The global market is projected to grow at a CAGR of 10.2% during the forecast period, 2024-2033.

The Cancer Stem Cells Market size was valued at USD 2,378.8 Million in 2024.

PURCHASE OPTIONS

$

3490


$

4490


$

5490


$

1950


powerbi pdf
$

6200

What You Get :

  • PDF Report Format.
  • Can be accessible by 1 single user.
  • Free 25% or 40 hours of customisation.
  • Free post-sale service assistance.
  • 15% discount on your next purchase.
  • Dedicated account Associate .
  • Permission to print the report.
  • Service guarantee available.
  • PDF and Excel Datasheet Formats.
  • Can be accessible upto 2 to 5 users.
  • Free 35% or 60 hours of customisation.
  • Free post-sale service assistance.
  • 25% discount on your next purchase.
  • Service guarantee available.
  • Personalised market brief by author.
  • Permission to print the report.
  • PDF, Excel and Power Point.
  • Can be accessible by unlimited users.
  • Free 40% or 80 hours of customisation.
  • Free post-sale service assistance.
  • 30% discount on your next purchase.
  • Permission to print the report.
  • Dedicated account manager.
  • Service guarantee available.
  • Excel Datasheet Format.
  • Customized access as per user request.
  • Upgradable to other licenses.
  • 15% discount on your next purchase.
  • Free 20% or 10 hours of customisation.
  • PDF, Excel, Power Point and Power BI.
  • Every Year Free Update ( Apr – Apr)
  • Personalized market brief by author
  • Can be accessible by unlimited users.
  • Free 50% or 90 hours of customization.
  • Up to 50 Company Profiles
  • Free post-sale service assistance with guarantee
  • 40% discount on your next purchase.
  • Permission to print the report.
  • Dedicated account team.
  • Service guarantee available.

Want to customize this report?
100% FREE CUSTOMIZATION!